Delving into the Latest Updates on Pharvaris Netherlands BV with Synapse

概览

疾病领域	数量

免疫系统疾病	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

B2 receptor(缓激肽B2受体)	1

关联

1

项与 Pharvaris Netherlands BV 相关的药物

Deucrictibant

靶点

B2 receptor

作用机制

B2 receptor拮抗剂

在研机构

Pharvaris Netherlands BV

原研机构

Pharvaris Netherlands BV

在研适应症

遗传性血管性水肿 [+2]

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

18

项与 Pharvaris Netherlands BV 相关的临床试验

CTIS2024-516248-24-00

/ Recruiting临床3期

A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema - PHA022121-C307

开始日期2025-03-28

申办/合作机构

Pharvaris Netherlands BV

CTIS2024-516247-62-00

/ Recruiting临床3期

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema - PHA022121-C305

开始日期2025-03-10

申办/合作机构

Pharvaris Netherlands BV

NCT06679881

/ Recruiting临床3期

A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema

开始日期2025-02-01

申办/合作机构

Pharvaris Netherlands BV

100 项与 Pharvaris Netherlands BV 相关的临床结果

登录后查看更多信息

0 项与 Pharvaris Netherlands BV 相关的专利（医药）

登录后查看更多信息

100 项与 Pharvaris Netherlands BV 相关的药物交易

登录后查看更多信息

100 项与 Pharvaris Netherlands BV 相关的转化医学

登录后查看更多信息